Abstract: A semiconductor device and a method of fabricating a semiconductor device, the device including a fin-type pattern extending in a first direction; a gate electrode extending in a second direction over the fin-type pattern, the second direction being different from the first direction; spacers on sidewalls of the gate electrode; a capping structure on the gate electrode and the spacers, the capping structure including a first capping pattern and a second capping pattern, the second capping pattern being on the first capping pattern; and an interlayer insulating film surrounding sidewalls of each of the spacers and sidewalls of the capping structure, the interlayer insulating film being in contact with the first capping pattern.

Abstract: A semiconductor device includes an active pattern; gate spacers on the active pattern defining a gate trench; a gate insulating layer along a sidewall and a bottom surface of the gate trench; a first conductive layer on the gate insulating layer; a second conductive layer on the first conductive layer in the gate trench; a third conductive layer on the second conductive layer in the gate trench and including a first portion between parts of the second conductive layer, and a second portion on the first portion and in contact with an upper surface of the second conductive layer; and a capping pattern on the second and third conductive layers and including a portion between the gate insulating layer and the second portion, and in contact with a sidewall of the second portion, wherein a width of the second portion is greater than a width of the first portion.

Abstract: The present invention relates to a fusion protein dimer comprising an IgE Fc receptor alpha subunit extracellular domain (Fc?RI?-ECD) and a fragment of anti-IL-4R antibody; and a composition for treating allergic diseases, comprising the same. The fusion protein dimer according to the present invention exhibits an excellent IgE-binding ability and an excellent serum IgE level-reducing effect. In addition, the present invention elicits a hyperimmune response of IgE, and thus has an excellent effect of inhibiting the activity of cytokines inducing allergic diseases, such as IL-4 and IL-13, and thus may be applied as a medicine for the use of treating or preventing IgE-mediated allergic diseases.

Abstract: The present invention relates to a fusion protein comprising an anti-LAG-3 antibody and IL-2 or a variant thereof. In the fusion protein according to the present invention, the anti-LAG-3 antibody moiety may bind to LAG-3, thereby regulating the binding of LAG-3 and MHCII. Moreover, the IL-2 protein or a variant thereof may regulate the activity of T cells. Therefore, a pharmaceutical composition comprising the fusion protein increases the immune activity in vivo and can be effectively used as an anticancer agent, and thus is highly industrially applicable.

Abstract: A pharmaceutical composition containing, as active ingredients, a fusion protein dimer including an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor is disclosed. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, the fusion protein dimer and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.

Abstract: An integrated molecular diagnosis apparatus including a buffer tube into which a sample collection tool collecting a sample is inserted, the buffer preparing a sample solution that contains nucleic acid extracted from the collected sample, a cartridge combined with the buffer tube and supplied with the sample solution, the cartridge transporting the sample solution to a reaction chamber through a fluid channel and performing a nucleic acid amplification reaction, and a diagnosis module main body detachably combined with the cartridge, the diagnosis module main body supplying heat at a predetermined temperature to the reaction chamber, detecting the nucleic acid amplification reaction, and determining whether or not a diagnosis target is present.

Abstract: There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.

Abstract: There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.

Abstract: A semiconductor device includes a first interlayer insulating film; a conductive connection structure provided in the first interlayer insulating film; a second interlayer insulating film provided on the first interlayer insulating film; a wiring structure provided in the second interlayer insulating film and connected to the conductive connection structure; and an insertion liner interposed between an upper surface of the conductive connection structure and the wiring structure, the insertion liner including carbon.

Abstract: A semiconductor device and a method of fabricating a semiconductor device, the device including a fin-type pattern extending in a first direction; a gate electrode extending in a second direction over the fin-type pattern, the second direction being different from the first direction; spacers on sidewalls of the gate electrode; a capping structure on the gate electrode and the spacers, the capping structure including a first capping pattern and a second capping pattern, the second capping pattern being on the first capping pattern; and an interlayer insulating film surrounding sidewalls of each of the spacers and sidewalls of the capping structure, the interlayer insulating film being in contact with the first capping pattern.

Abstract: A semiconductor device includes a first interlayer insulating film; a conductive connection structure provided in the first interlayer insulating film; a second interlayer insulating film provided on the first interlayer insulating film; a wiring structure provided in the second interlayer insulating film and connected to the conductive connection structure; and an insertion liner interposed between an upper surface of the conductive connection structure and the wiring structure, the insertion liner including carbon.

Abstract: A semiconductor device and a method of fabricating a semiconductor device, the device including a fin-type pattern extending in a first direction; a gate electrode extending in a second direction over the fin-type pattern, the second direction being different from the first direction; spacers on sidewalls of the gate electrode; a capping structure on the gate electrode and the spacers, the capping structure including a first capping pattern and a second capping pattern, the second capping pattern being on the first capping pattern; and an interlayer insulating film surrounding sidewalls of each of the spacers and sidewalls of the capping structure, the interlayer insulating film being in contact with the first capping pattern.

Abstract: The present invention relates to an antibody against delta-like 1 homolog (Drosophila) (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.

Abstract: A small-sized motor apparatus for a vehicle, includes: a frame; a drive shaft mounted to the frame, a driven shaft to rotate dependently on the drive shaft, the driven shaft including a second worm gear; a cover coupled to the frame; a plate-shaped washer member; and a gap spring member preventing an axial movement of the driven shaft, the gap spring member being assembled in a radial direction of the driven shaft and installed such that one side of the gap spring member is contact-supported by the plate-shaped washer member and the other side of the gap spring member is supported by the frame, wherein the frame includes a slide groove that accommodates both ends of the gap spring member and the plate-shaped washer member and restricts the gap spring member from moving in an axial direction of the driven shaft.

Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.

Abstract: The present invention relates to a pharmaceutical composition for preventing greying of hair, and preventing or treating poliosis or vitiligo. The pharmaceutical composition of the present invention increases intracellular melanin content, accelerates or increases melanoblast migration, pre-emptively prevents gray hair formation, and accelerates dark hair formation, and thus may be beneficially used in the prevention or alleviation of greying of hair, and in the prevention, alleviation or treatment of poliosis or vitiligo.

Abstract: The present invention relates to an antibody against delta-like 1 homolog (Drosophila) (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.

Abstract: A semiconductor device and a method of fabricating a semiconductor device, the device including a fin-type pattern extending in a first direction; a gate electrode extending in a second direction over the fin-type pattern, the second direction being different from the first direction; spacers on sidewalls of the gate electrode; a capping structure on the gate electrode and the spacers, the capping structure including a first capping pattern and a second capping pattern, the second capping pattern being on the first capping pattern; and an interlayer insulating film surrounding sidewalls of each of the spacers and sidewalls of the capping structure, the interlayer insulating film being in contact with the first capping pattern.

Abstract: A method for monitoring a downlink control channel, the method performed by a user equipment (UE) configured with multiple carriers includes determining whether to monitor the downlink control channel within either one UE-specific search space or a plurality of UE-specific search spaces, and monitoring the downlink control channel within the plurality of UE-specific search spaces if carrier index is configured, wherein each of the plurality of the UE-specific search spaces is determined based on the carrier index.

Abstract: Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.